West Pharmaceutical Services Inc. (NYSE:WST) Position Cut by Chatham Capital Group Inc.

Chatham Capital Group Inc. decreased its position in West Pharmaceutical Services Inc. (NYSE:WST) by 25.4% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 13,514 shares of the medical instruments supplier’s stock after selling 4,613 shares during the period. Chatham Capital Group Inc.’s holdings in West Pharmaceutical Services were worth $1,489,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in WST. Vanguard Group Inc raised its holdings in shares of West Pharmaceutical Services by 2.0% in the 3rd quarter. Vanguard Group Inc now owns 7,067,729 shares of the medical instruments supplier’s stock valued at $872,652,000 after purchasing an additional 139,098 shares in the last quarter. State of Alaska Department of Revenue raised its stake in West Pharmaceutical Services by 1.7% during the 4th quarter. State of Alaska Department of Revenue now owns 8,056 shares of the medical instruments supplier’s stock worth $789,000 after acquiring an additional 131 shares in the last quarter. Virtu Financial LLC acquired a new stake in West Pharmaceutical Services during the 4th quarter worth $239,000. Oakbrook Investments LLC raised its stake in West Pharmaceutical Services by 18.8% during the 4th quarter. Oakbrook Investments LLC now owns 5,675 shares of the medical instruments supplier’s stock worth $556,000 after acquiring an additional 900 shares in the last quarter. Finally, Fisher Asset Management LLC raised its stake in West Pharmaceutical Services by 0.3% during the 4th quarter. Fisher Asset Management LLC now owns 924,964 shares of the medical instruments supplier’s stock worth $90,674,000 after acquiring an additional 2,463 shares in the last quarter. Institutional investors own 91.91% of the company’s stock.

WST has been the topic of several research analyst reports. Zacks Investment Research lowered shares of West Pharmaceutical Services from a “hold” rating to a “sell” rating in a research note on Friday, April 19th. William Blair assumed coverage on shares of West Pharmaceutical Services in a research note on Tuesday, April 23rd. They set an “outperform” rating and a $112.16 price target on the stock. Finally, Jefferies Financial Group downgraded shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating and set a $122.00 price objective on the stock. in a research report on Wednesday, May 1st.

In other news, VP Daniel Malone sold 4,458 shares of West Pharmaceutical Services stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $123.03, for a total value of $548,467.74. Following the sale, the vice president now owns 33,478 shares of the company’s stock, valued at $4,118,798.34. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.70% of the stock is owned by insiders.

West Pharmaceutical Services stock traded down $1.22 during midday trading on Friday, hitting $120.68. 149,789 shares of the company’s stock were exchanged, compared to its average volume of 389,565. West Pharmaceutical Services Inc. has a 12-month low of $91.75 and a 12-month high of $125.09. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.13 and a current ratio of 2.88. The company has a market capitalization of $8.98 billion, a P/E ratio of 42.95, a PEG ratio of 3.71 and a beta of 1.30.

West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, April 25th. The medical instruments supplier reported $0.74 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.66 by $0.08. The business had revenue of $443.50 million for the quarter, compared to the consensus estimate of $431.00 million. West Pharmaceutical Services had a net margin of 12.53% and a return on equity of 16.38%. The business’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.62 earnings per share. As a group, equities analysts expect that West Pharmaceutical Services Inc. will post 2.88 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, August 7th. Stockholders of record on Wednesday, July 24th will be issued a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 0.50%. The ex-dividend date of this dividend is Tuesday, July 23rd. West Pharmaceutical Services’s payout ratio is 21.35%.

COPYRIGHT VIOLATION WARNING: This news story was first published by Rockland Register and is the property of of Rockland Register. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://rocklandregister.com/2019/06/14/chatham-capital-group-inc-sells-4613-shares-of-west-pharmaceutical-services-inc-wst.html.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

See Also: The Role of a Fiduciary and Individual Investors

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.